Test Price
2,600 AED✅ Home Collection Available
Next-Generation Sequencing: Alexander Disease Test in UAE | 2600 AED | 2026 DHA Guidelines
تحليل تسلسل الجيل التالي لمرض ألكساندر في الإمارات | 2600 درهم | معتمد من هيئة الصحة بدبي 2026
Executive Summary
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via NGS with orthogonal Sanger confirmation, processed in our ISO 9001:2015 accredited laboratory (Cert: INT/EGQ/2509DA/3139).
- ✓ Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy service, available 8 AM to 11 PM daily across all emirates.
- ✓ Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance for result interpretation provided by DHA-licensed clinical consultants.
- ✓ Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731 — our team verifies coverage before your appointment.
الملخص التنفيذي
يقدم هذا الفحص التشخيصي المتقدم تحليلاً شاملاً لتسلسل الجيل التالي (NGS) مع تأكيد بطريقة سانجر لجين GFAP المرتبط بمرض ألكساندر، وهو اضطراب تنكسي عصبي نادر يتميز بالتشنج والنوبات الصرعية وتأخر النمو الحركي. نضمن دقة تشخيصية استثنائية تصل إلى 99.9% من خلال مختبراتنا المعتمدة دولياً بموجب شهادة ISO 9001:2015 وترخيص هيئة الصحة بدبي رقم 9834453، مع خدمة سحب دم منزلية متميزة عبر فريق تمريض متنقل وفق معايير سلسلة التبريد الدولية، وتوجيه سريري هاتفي شامل بعد صدور النتائج لضمان الفهم الكامل للتقرير الجيني واتخاذ القرارات العلاجية المناسبة.
Clinical Overview
The Alexander Disease NGS Test is a comprehensive genetic analysis targeting the GFAP gene mutations responsible for this rare neurodegenerative disorder, utilizing Next-Generation Sequencing with orthogonal Sanger confirmation for 99.9% diagnostic accuracy. This ISO 9001:2015 certified test provides definitive molecular diagnosis for patients presenting with spasticity, seizures, macrocephaly, and developmental delays, enabling precise clinical management, genotype-phenotype correlation, and comprehensive family genetic counseling in accordance with UAE genetic testing regulations.
يوفر فحص تسلسل الجيل التالي لمرض ألكساندر تحليلاً جينياً شاملاً لطفرة جين GFAP المرتبطة بهذا الاضطراب العصبي التنكسي النادر، مما يتيح تشخيصاً جزيئياً دقيقاً للمرضى الذين يعانون من التشنج والنوبات الصرعية وتضخم الرأس، ويدعم اتخاذ القرارات السريرية المبنية على الأدلة وفقاً لإرشادات هيئة الصحة بدبي لعام 2026.
| Parameter | Our Test — Alexander Disease NGS | Closest Alternative — Standard NGS Panel |
|---|---|---|
| Methodology | NGS + Orthogonal Sanger Sequencing Confirmation | NGS Only (no orthogonal confirmation) |
| Diagnostic Sensitivity | 99.9% | ~95% (potential false positives/negatives) |
| Turnaround Time | 40 Working Days (8 Weeks) | 60–90 Working Days (12–18 Weeks) |
| Certification | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) | Variable / Unverified |
| Pre-Test Consent | Form 37 Mandatory (UAE-Compliant Genetic Counseling) | Often Omitted |
| Post-Test Guidance | Included — Telephonic Clinical Guidance | Not Included |
Physician Insight & Safety Protocol
Clinical Note from Dr. Prabhakar Reddy — DHA License: 61713011, Consultant Neurologist & Clinical Geneticist
"The NGS Alexander Disease Test provides critical genetic confirmation, but results must always be interpreted within the full clinical picture by your treating neurologist or pediatrician. A positive GFAP mutation confirms the molecular diagnosis, yet disease severity and progression vary significantly among patients — even within the same family. I strongly recommend all patients and their families undergo comprehensive pre- and post-test genetic counseling to fully understand the implications of the results, including inheritance patterns and reproductive options."
⚠ Medication Warning: Do not discontinue prescribed medication without consulting your doctor. Genetic test results are not a substitute for ongoing clinical management. Abrupt cessation of anti-epileptic medications or muscle relaxants can lead to serious adverse events including status epilepticus.
⚠ Exclusion Criteria & Emergency Red Flags
Exclusion Criteria (Do Not Proceed Without Clinical Clearance):
- Patient is hemodynamically unstable or currently admitted to intensive care
- Incomplete or unsigned Whole Exome Sequencing Consent Form (Form 37)
- Sample collected in incorrect tube type (must be Lavender Top EDTA — no heparin, no serum separator)
- Previously frozen sample (frozen whole blood compromises DNA integrity — strictly refrigerated transport only)
- Patient has undergone allogeneic bone marrow transplantation within the past 90 days (donor DNA may confound results)
Emergency Red Flags — Seek Immediate Medical Attention:
- Status epilepticus or prolonged seizures lasting more than 5 minutes
- Acute loss of consciousness or unresponsiveness
- Severe respiratory distress or apnea episodes
- Sudden severe spasticity with complete loss of mobility
- Signs of raised intracranial pressure: severe headache, vomiting, blurred vision, altered mental status
- Acute dysphagia with risk of aspiration
If you or the patient experience any of the above red-flag symptoms, proceed immediately to the nearest emergency department. Do not wait for test results.
Patient FAQ & Clinical Guidance
Q1: What is the Alexander Disease NGS Test and who should consider it?
The Alexander Disease NGS Test analyzes the GFAP gene to confirm or rule out Alexander disease diagnosis definitively in symptomatic patients. This test is specifically recommended for infants and children presenting with macrocephaly, developmental regression, spasticity, and seizure disorders, as well as adults with atypical neurological symptoms suggestive of the later-onset form. It is also indicated for asymptomatic siblings of confirmed cases seeking carrier status determination, in full compliance with UAE CDS Law 2026 provisions for genetic testing of minors, which require parental or legal guardian consent and mandatory genetic counseling.
Q2: How is the sample collected and what is the turnaround time for results?
A certified phlebotomist collects 10 mL of whole blood via our ISO-certified cold-chain home collection service for maximum convenience. The sample is drawn into two Lavender Top (EDTA) tubes, immediately refrigerated — never frozen — and transported under strict cold-chain protocols to our ISO 9001:2015 accredited laboratory. Patients must also provide a duly filled and signed Whole Exome Sequencing Consent Form (Form 37), which is mandatory under UAE genetic testing regulations. The report is delivered within 40 working days (approximately 8 weeks), reflecting the rigorous NGS sequencing, bioinformatics analysis, and Sanger confirmation required for 99.9% diagnostic accuracy. Sample collection is available daily by 9 AM, and our VIP mobile phlebotomy team serves all seven emirates from 8 AM to 11 PM.
Q3: Is the Alexander Disease NGS Test covered by health insurance in the UAE?
Insurance coverage varies by provider, but our team offers direct billing verification via WhatsApp at +971545488731 before your appointment. Many UAE medical insurance plans, including those under the DHA mandatory health insurance scheme and Thiqa (Abu Dhabi), provide partial or full coverage for medically indicated genetic testing when accompanied by a referral from a DHA-licensed neurologist or pediatrician. We strongly recommend contacting our insurance verification team via WhatsApp before scheduling your home collection to confirm your specific plan's coverage, pre-authorization requirements, and any out-of-pocket co-payment. For patients without insurance coverage, the test is available at a transparent all-inclusive price of 2600 AED, covering home collection, cold-chain transport, NGS sequencing with Sanger confirmation, bioinformatics analysis, and post-test telephonic clinical guidance.
UAE Regulatory & Legal Compliance
- Federal Decree-Law No. 41 of 2024 (Article 87): This facility adheres to all provisions governing clinical laboratory operations, diagnostic accuracy, and patient safety within the United Arab Emirates. All testing is conducted in full compliance with this decree.
- UAE Clinical Data Standards (CDS) Law 2026 — Minors: Genetic testing of individuals under 18 years of age requires mandatory parental or legal guardian consent with documented genetic counseling. Form 37 compliance is strictly enforced.
- UAE Personal Data Protection Law (PDPL): All patient genomic data, test results, and personally identifiable health information are encrypted, stored securely within UAE-based servers, and processed in strict accordance with UAE PDPL requirements. No data is transferred outside the UAE without explicit patient consent.
- DHA Facility License: 9834453 — Issued by Dubai Health Authority, valid and in good standing.
- ISO 9001:2015 Certification: Cert: INT/EGQ/2509DA/3139 — Internationally recognized quality management system certification covering all pre-analytical, analytical, and post-analytical laboratory processes.
- CDS Law 2026 — Genetic Counseling Mandate: Pre-test and post-test genetic counseling by a DHA-licensed genetics professional is strongly recommended and, for pediatric cases, mandated by UAE law.
Schedule Your Alexander Disease NGS Today
Insurance Verification | Home Collection | 99.9% Accuracy | ISO Certified
Available 8 AM – 11 PM | All Emirates | DHA Licensed | ISO 9001:2015 Certified
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians